News & Media

RAS pathway-driven cancers—such as low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are difficult to treat. For patients with these forms of cancer, currently available treatments face resistance mechanisms and aren’t effective and often have side effects that make them difficult to tolerate. This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Julissa Viana via email at

Press Releases

All Verastem Oncology "Press Releases" are archived here.

Media Resources

Headquartered in Needham, MA, Verastem Oncology Inc. (NASDAQ: VSTM), is a biopharmaceutical company focused on bringing better treatment options to patients who are battling RAS pathway-driven cancers. These types of cancers—which include low-grade serous ovarian cancer and KRAS-mutant non-small cell lung cancer—are extremely difficult to treat and currently available therapeutic options are limited and suboptimal. That’s why new options are needed, and we’re committed to delivering them.


For media interested in Verastem Oncology, please contact Julissa Viana via email at You can also refer to the resources below, which contain information about what we do, our leadership team and our financials.



To stay updated on the latest news about Verastem Oncology, sign up for alerts.

Previous and Upcoming Events

Below are past or scheduled upcoming events either hosted or sponsored by Verastem Oncology.

Verastem Analyst Breakfast at ASCO

05/31/2015 6:30 AM (CDT)

Progress Updates and 2015 Outlook

01/08/2015 4:30 PM (EST)

Articles Featuring Verastem Oncology


Julissa Viana
Investor Relations

Tweets by @VerastemOncolog

We were encouraged to see @VerastemOncolog, recipients of PanCAN’s Therapeutic Accelerator Award, present the initial data for their RAMP 205 study at #ASCO24. The goal for this award is to create better therapies for #pancreaticcancer and bring them to patients more quickly.

ASCO 2024: @VerastemOncolog's CEO comments on a volatile week and #ASCO24 data in pancreatic cancer. $VSTM

Full video: